July 5, 2016
LA JOLLA—The Salk Institute will celebrate 21 years of Symphony at Salk, its signature concert under the stars, with Broadway luminary Kelli O’Hara and the incomparable San Diego Symphony led by guest conductor Maestro Thomas Wilkins on Saturday, August 20.
The gala evening concert on the courtyard of the Louis Kahn-designed Institute will showcase O’Hara performing her Broadway showstoppers and selections from the Great American Songbook. Her portrayal of Anna Leonowens in the critically acclaimed revival of The King and I garnered her the 2015 Tony Award for Best Leading Actress in a Musical. Since her Broadway debut in Jekyll & Hyde in 2000, she has moved from one critical and commercial success to another, earning numerous Tony, Drama Desk, Drama League and Outer Critics Circle nominations. A recent New York Times review of her operatic turn in Dido and Aeneas raved, “Ms. O’Hara can sign a Rodgers and Hammerstein number as if she were talking to you, while still bringing exquisite sound to her phrases.”
Individual tickets for Symphony at Salk are $300 and include a champagne reception and gourmet dinner. All proceeds support the Institute’s wide-ranging scientific inquiries that have yielded more than 50 years of life-changing discoveries, directly influencing areas as diverse as cancer, Alzheimer’s Parkinson’s, metabolic diseases, ALS, schizophrenia, autism, spinal cord injuries, crop yields and world hunger. Proceeds also support Salk’s award-winning educational outreach programs that have helped generations of students discover their passion for research and explore careers in science.
Tickets can be purchased online at www.salk.edu/symphony. For more information, call (858) 597-0657.
Büro für Kommunikation
Telefon: (858) 453-4100
press@salk.edu
Das Salk Institute ist ein unabhängiges, gemeinnütziges Forschungsinstitut, das 1960 von Jonas Salk, dem Entwickler des ersten sicheren und wirksamen Polio-Impfstoffs, gegründet wurde. Die Aufgabe des Instituts besteht darin, grundlegende, kooperative und risikofreudige Forschung voranzutreiben, die sich mit den dringendsten Herausforderungen der Gesellschaft befasst, darunter Krebs, Alzheimer und die Gefährdung der Landwirtschaft. Diese Grundlagenforschung bildet die Basis für alle translationalen Bemühungen und führt zu Erkenntnissen, die neue Medikamente und Innovationen weltweit ermöglichen.
